menu
    • menu
    [{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus gasseri BGP345A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioGaia Pharma \/ BioFortis","highestDevelopmentStatusID":"8","companyTruncated":"BioGaia Pharma \/ BioFortis"},{"orgOrder":0,"company":"Scandinavian Biopharma","sponsor":"G\u00f6teborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Tetravalent Etec Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Scandinavian Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Scandinavian Biopharma \/ G\u00f6teborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia","highestDevelopmentStatusID":"8","companyTruncated":"Scandinavian Biopharma \/ G\u00f6teborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"X842","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cinclus Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Parexel"},{"orgOrder":0,"company":"OncoZenge","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OncoZenge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"OncoZenge \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"OncoZenge \/ University of California"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoZenge

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            OncoZenge

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : University of California

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            OncoZenge Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge

                            Details : The partnership focuses on a patient engagement study in managing oral mucositis pain, while exploring potential pathways toward a future IND application for BupiZenge.

                            Product Name : BupiZenge

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 17, 2025

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : University of California

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cinclus Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Zentiva

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Zentiva Inks €220M Deal for Former AstraZeneca GI Drug in Europe

                            Details : Under the licensing agreement, Zentiva will hold the rights for the commercialization and manufacturing of linaprazan glurate, in Europe.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $14.7 million

                            May 22, 2025

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Zentiva

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Reuteri

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Connection Study Continues After Pre-scheduled Data Monitoring Committee (DMC) Review

                            Details : IBP-9414 (lactobacillus Reuteri), strain-specific attributes which affect the NEC pathogenesis is world’s first approved probiotic drug with the goal to prevent life-threatening diseases in premature infants.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : Lactobacillus Reuteri

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioGaia Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioGaia Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus gasseri BGP345A

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : BioFortis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications

                            Details : Lactobacillus gasseri BGP345A is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Induced Constipation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 24, 2021

                            Lead Product(s) : Lactobacillus gasseri BGP345A

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : BioFortis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cinclus Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : X842

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 We...

                            Details : X842 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Esophagitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 24, 2021

                            Lead Product(s) : X842

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Reuteri

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Infant Bacterial Therapeutics Expands The Connection Study to Include Infants with a Birth Weight Below 750 Gr...

                            Details : IBT is developing the drug candidate IBP-9414, contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk, for the prevention of necrotizing enterocolitis and improvement of feeding tolerance i...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 29, 2021

                            Lead Product(s) : Lactobacillus Reuteri

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Reuteri

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020

                            Details : IBT is currently developing IBP-9414 to prevent necrotizing enterocolitis, and to improve feeding tolerance in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 05, 2021

                            Lead Product(s) : Lactobacillus Reuteri

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cinclus Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cinclus Pharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Fourth Swedish National Pension Fund

                            Deal Size : $25.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophag...

                            Details : The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 04, 2020

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Fourth Swedish National Pension Fund

                            Deal Size : $25.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Scandinavian Biopharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Scandinavian Biopharma

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetravalent Etec Vaccine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Göteborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)

                            Details : Tetravalent Etec Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diarrhea.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 02, 2018

                            Lead Product(s) : Tetravalent Etec Vaccine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Göteborg University | United Medix Laboratories Ltd. | Medfiles Ltd | University of Helsinki | University of Virginia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Infant Bacterial Therapeutics

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBP-9414

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IBP-9414 for the Prevention of Necrotizing Enterocolitis

                            Details : IBP-9414 is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Enterocolitis, Necrotizing.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 16, 2015

                            Lead Product(s) : IBP-9414

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth